$REGN
REGENERON PHARMACEUTICALS, INC.

2017 Q2 Form 10-Q Financial Statement

#000153217617000027 Filed on August 03, 2017

View on sec.gov

Income Statement

Concept 2017 Q2 2016 Q2
Revenue $1.470B $1.213B
YoY Change 21.23% 21.43%
Cost Of Revenue $42.13M $41.25M
YoY Change 2.15% -32.22%
Gross Profit $1.428B $1.171B
YoY Change 21.91% 24.91%
Gross Profit Margin 97.13% 96.6%
Selling, General & Admin $306.9M $292.0M
YoY Change 5.09% 67.27%
% of Gross Profit 21.49% 24.93%
Research & Development $510.0M $559.9M
YoY Change -8.92% 43.45%
% of Gross Profit 35.71% 47.8%
Depreciation & Amortization $35.10M $25.00M
YoY Change 40.4% 63.4%
% of Gross Profit 2.46% 2.13%
Operating Expenses $816.9M $852.0M
YoY Change -4.12% 50.81%
Operating Profit $550.3M $291.6M
YoY Change 88.7% -15.44%
Interest Expense $5.401M -$1.251M
YoY Change -531.73% -145.52%
% of Operating Profit 0.98% -0.43%
Other Income/Expense, Net -$24.46M $628.0K
YoY Change -3995.22% -103.72%
Pretax Income $525.9M $292.3M
YoY Change 79.93% -10.9%
Income Tax $138.1M $96.04M
% Of Pretax Income 26.26% 32.86%
Net Earnings $387.7M $196.2M
YoY Change 97.59% 0.81%
Net Earnings / Revenue 26.37% 16.18%
Basic Earnings Per Share $3.66 $1.88
Diluted Earnings Per Share $3.34 $1.69
COMMON SHARES
Basic Shares Outstanding 106.0M shares 104.6M shares
Diluted Shares Outstanding 116.1M shares 116.2M shares

Balance Sheet

Concept 2017 Q2 2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.268B $1.045B
YoY Change 21.34% 73.01%
Cash & Equivalents $744.3M $646.5M
Short-Term Investments $524.0M $399.0M
Other Short-Term Assets $381.0M $158.0M
YoY Change 141.14% 11.27%
Inventory $554.3M $316.1M
Prepaid Expenses
Receivables $1.420B $1.432B
Other Receivables $0.00 $0.00
Total Short-Term Assets $3.860B $3.209B
YoY Change 20.28% 40.55%
LONG-TERM ASSETS
Property, Plant & Equipment $2.262B $1.773B
YoY Change 27.57% 33.69%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $1.065B $590.0M
YoY Change 80.51% 0.0%
Other Assets $36.96M $6.715M
YoY Change 450.45% 62.28%
Total Long-Term Assets $4.246B $2.996B
YoY Change 41.75% 33.52%
TOTAL ASSETS
Total Short-Term Assets $3.860B $3.209B
Total Long-Term Assets $4.246B $2.996B
Total Assets $8.106B $6.205B
YoY Change 30.64% 37.07%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $151.0M $102.0M
YoY Change 48.04% -21.54%
Accrued Expenses $542.0M $488.0M
YoY Change 11.07% 22.31%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $1.029B $951.6M
YoY Change 8.14% 58.19%
LONG-TERM LIABILITIES
Long-Term Debt $701.0M $362.0M
YoY Change 93.65% -6.7%
Other Long-Term Liabilities $115.9M $119.5M
YoY Change -3.01% 57.1%
Total Long-Term Liabilities $115.9M $119.5M
YoY Change -3.01% 57.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.029B $951.6M
Total Long-Term Liabilities $115.9M $119.5M
Total Liabilities $2.586B $2.128B
YoY Change 21.48% 79.08%
SHAREHOLDERS EQUITY
Retained Earnings $2.385B $1.230B
YoY Change 93.85% 152.47%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $316.2M $316.1M
YoY Change 0.06% 10.09%
Treasury Stock Shares 3.764M shares 3.762M shares
Shareholders Equity $5.521B $4.077B
YoY Change
Total Liabilities & Shareholders Equity $8.106B $6.205B
YoY Change 30.64% 37.07%

Cashflow Statement

Concept 2017 Q2 2016 Q2
OPERATING ACTIVITIES
Net Income $387.7M $196.2M
YoY Change 97.59% 0.81%
Depreciation, Depletion And Amortization $35.10M $25.00M
YoY Change 40.4% 63.4%
Cash From Operating Activities -$30.60M $399.5M
YoY Change -107.66% 54.97%
INVESTING ACTIVITIES
Capital Expenditures -$54.80M -$138.8M
YoY Change -60.52% -42.14%
Acquisitions
YoY Change
Other Investing Activities -$115.5M -$187.2M
YoY Change -38.3% 42.03%
Cash From Investing Activities -$170.5M -$326.0M
YoY Change -47.7% -12.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 133.5M -31.20M
YoY Change -527.88% 791.43%
NET CHANGE
Cash From Operating Activities -30.60M 399.5M
Cash From Investing Activities -170.5M -326.0M
Cash From Financing Activities 133.5M -31.20M
Net Change In Cash -67.60M 42.30M
YoY Change -259.81% -136.06%
FREE CASH FLOW
Cash From Operating Activities -$30.60M $399.5M
Capital Expenditures -$54.80M -$138.8M
Free Cash Flow $24.20M $538.3M
YoY Change -95.5% 8.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2017
dei Document Period End Date
DocumentPeriodEndDate
2017-06-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0000872589
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
REGENERON PHARMACEUTICALS INC
CY2015Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
50700000 USD
CY2016Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
39300000 USD
CY2016Q4 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
28200000 USD
CY2017Q2 regn Accrued Capital Expenditures
AccruedCapitalExpenditures
30900000 USD
CY2016Q4 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
91753000 USD
CY2017Q2 regn Accrued Clinical Trial Expense Current
AccruedClinicalTrialExpenseCurrent
101570000 USD
CY2016Q4 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
159985000 USD
CY2017Q2 regn Accruedsalesrelatedchargesdeductionsandroyalties
Accruedsalesrelatedchargesdeductionsandroyalties
214374000 USD
CY2017Q1 regn Aggregatefundingadvancedbytheparticipants
Aggregatefundingadvancedbytheparticipants
720000000 USD
CY2016Q4 regn Capitalandfacilityleaseobligationscurrent
Capitalandfacilityleaseobligationscurrent
129557000 USD
CY2017Q2 regn Capitalandfacilityleaseobligationscurrent
Capitalandfacilityleaseobligationscurrent
0 USD
CY2016Q4 regn Capitalandfacilityleaseobligationsnoncurrent
Capitalandfacilityleaseobligationsnoncurrent
351569000 USD
CY2017Q2 regn Capitalandfacilityleaseobligationsnoncurrent
Capitalandfacilityleaseobligationsnoncurrent
701173000 USD
CY2016Q2 regn Costofmanufacturing
Costofmanufacturing
27786000 USD
regn Costofmanufacturing
Costofmanufacturing
60596000 USD
CY2017Q2 regn Costofmanufacturing
Costofmanufacturing
60788000 USD
regn Costofmanufacturing
Costofmanufacturing
83703000 USD
CY2016Q4 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
115267000 USD
CY2017Q2 regn Deferred Revenue From Related Party Current
DeferredRevenueFromRelatedPartyCurrent
184452000 USD
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
1130000 shares
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5362000 USD
CY2016Q4 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
503474000 USD
CY2017Q2 regn Deferred Revenue From Related Party Noncurrent
DeferredRevenueFromRelatedPartyNoncurrent
443904000 USD
CY2016Q4 regn Facility Purchase Price
FacilityPurchasePrice
720000000 USD
CY2016Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
473000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
471000 shares
CY2017Q2 regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
501000 shares
regn Incremental Common Shares Attributable To Nonvested Restricted Shares
IncrementalCommonSharesAttributableToNonvestedRestrictedShares
493000 shares
CY2017Q1 regn Initialtermoflease
Initialtermoflease
P5Y
regn Loss Contingency Damages Soughtperunitproduced.
LossContingencyDamagesSoughtperunitproduced.
10000 EUR
CY2016Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
191896000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
371488000 USD
CY2017Q2 regn Other Collaboration Revenue
OtherCollaborationRevenue
210355000 USD
regn Other Collaboration Revenue
OtherCollaborationRevenue
404294000 USD
CY2016Q4 regn Paymenttowardspurchasepriceof Tarrytownfacility
PaymenttowardspurchasepriceofTarrytownfacility
57000000 USD
CY2017Q1 regn Potentialextendedtermoflease
Potentialextendedtermoflease
P5Y
CY2017Q1 regn Reimbursementreceivedbythe Company
ReimbursementreceivedbytheCompany
57000000 USD
CY2017Q1 regn Tarrytownfacilitycapitalandfacilityleaseobligations
Tarrytownfacilitycapitalandfacilityleaseobligations
720000000 USD
CY2016Q4 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
175263000 USD
CY2017Q2 us-gaap Accounts And Notes Receivable Net
AccountsAndNotesReceivableNet
203066000 USD
CY2016Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
879096000 USD
CY2017Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
716364000 USD
CY2016Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
134984000 USD
CY2017Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
151372000 USD
CY2016Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1343368000 USD
CY2017Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1420403000 USD
CY2016Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
92989000 USD
CY2017Q2 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
221078000 USD
CY2016Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12840000 USD
CY2017Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2348000 USD
CY2016Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3029993000 USD
CY2017Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
3449622000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
66885000 USD
us-gaap Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities
AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
-311344000 USD
CY2016Q4 us-gaap Assets
Assets
6973466000 USD
CY2017Q2 us-gaap Assets
Assets
8106373000 USD
CY2016Q4 us-gaap Assets Current
AssetsCurrent
3180188000 USD
CY2017Q2 us-gaap Assets Current
AssetsCurrent
3860051000 USD
CY2016Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1367741000 USD
CY2017Q2 us-gaap Available For Sale Securities
AvailableForSaleSecurities
1588214000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
6241000 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11884000 USD
CY2016Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
18987000 USD
CY2017Q2 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
9519000 USD
CY2016Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1380487000 USD
CY2017Q2 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
1585849000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
58000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
5000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
18987000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLoss
9519000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
920357000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionFairValue
825427000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
18929000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9514000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
883950000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Less Than Twelve Months Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue
817983000 USD
CY2016Q4 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
36407000 USD
CY2017Q2 us-gaap Available For Sale Securities Continuous Unrealized Loss Position Twelve Months Or Longer Fair Value
AvailableForSaleSecuritiesContinuousUnrealizedLossPositionTwelveMonthsOrLongerFairValue
7444000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
815041000 USD
CY2017Q2 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
1004308000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
503481000 USD
CY2017Q2 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
523537000 USD
CY2016Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1318522000 USD
CY2017Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
1527845000 USD
us-gaap Available For Sale Securities Income Tax Expense On Change In Unrealized Holding Gain Or Loss
AvailableForSaleSecuritiesIncomeTaxExpenseOnChangeInUnrealizedHoldingGainOrLoss
1600000.0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
0 USD
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
201200000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
809102000 USD
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
646508000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
535203000 USD
CY2017Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
744313000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-162594000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
209110000 USD
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
197058000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
374235000 USD
CY2017Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
395976000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
651863000 USD
CY2016Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
41247000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
120189000 USD
CY2017Q2 us-gaap Cost Of Goods Sold
CostOfGoodsSold
42133000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
103386000 USD
CY2016Q2 us-gaap Costs And Expenses
CostsAndExpenses
921001000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1792542000 USD
CY2017Q2 us-gaap Costs And Expenses
CostsAndExpenses
919804000 USD
us-gaap Costs And Expenses
CostsAndExpenses
1808253000 USD
CY2016Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
116397000 USD
CY2017Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
127804000 USD
CY2016Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
327298000 USD
CY2017Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
295621000 USD
CY2016Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
825303000 USD
CY2017Q2 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
882980000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
48006000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
73241000 USD
CY2016Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.61
CY2017Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
3.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
6.02
CY2016Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.69
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.24
CY2017Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
3.34
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
5.51
CY2016Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.329
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.393
CY2017Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.263
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.336
CY2016Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
153086000 USD
CY2017Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
146438000 USD
CY2016Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2017Q2 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0 USD
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
CY2017Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0 USD
CY2016Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
CY2017Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
0 USD
CY2017Q2 us-gaap Gain Loss On Interest Rate Cash Flow Hedge Ineffectiveness
GainLossOnInterestRateCashFlowHedgeIneffectiveness
0 USD
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
292256000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
622407000 USD
CY2017Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
525850000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
958139000 USD
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
96038000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
244804000 USD
CY2017Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
138106000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
321464000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
133925000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-147232000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
284178000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
232927000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
162652000 USD
us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
57737000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
65850000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10655000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
72888000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
151544000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-57086000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
77168000 USD
CY2016Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
984000 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2016Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
121000 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2016Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10141000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
10433000 shares
CY2017Q2 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9602000 shares
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
9310000 shares
CY2016Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-1251000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3891000 USD
CY2017Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-5401000 USD
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12902000 USD
CY2016Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
373000 USD
CY2017Q2 us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
us-gaap Interest On Convertible Debt Net Of Tax
InterestOnConvertibleDebtNetOfTax
0 USD
CY2016Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
13334000 USD
CY2017Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
33021000 USD
CY2016Q4 us-gaap Inventory Net
InventoryNet
399356000 USD
CY2017Q2 us-gaap Inventory Net
InventoryNet
554320000 USD
CY2016Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
92287000 USD
CY2017Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
170273000 USD
CY2016Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
202301000 USD
CY2017Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
162718000 USD
CY2016Q2 us-gaap Inventory Write Down
InventoryWriteDown
2000000 USD
us-gaap Inventory Write Down
InventoryWriteDown
6300000 USD
CY2017Q2 us-gaap Inventory Write Down
InventoryWriteDown
2700000 USD
us-gaap Inventory Write Down
InventoryWriteDown
9100000 USD
CY2016Q4 us-gaap Liabilities
Liabilities
2524221000 USD
CY2017Q2 us-gaap Liabilities
Liabilities
2585635000 USD
CY2016Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6973466000 USD
CY2017Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
8106373000 USD
CY2016Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1241495000 USD
CY2017Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1029017000 USD
us-gaap Loss Contingency Damages Sought Value
LossContingencyDamagesSoughtValue
10000000 EUR
CY2016Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
503481000 USD
CY2017Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
523537000 USD
CY2016Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
864260000 USD
CY2017Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1064677000 USD
CY2016Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
CY2017Q2 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-237387000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
194331000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-369695000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-310552000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
444488000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
325331000 USD
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
196218000 USD
us-gaap Net Income Loss
NetIncomeLoss
377603000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
387744000 USD
us-gaap Net Income Loss
NetIncomeLoss
636675000 USD
CY2016Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
196218000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
377976000 USD
CY2017Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
387744000 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
636675000 USD
CY2016Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
628000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1471000 USD
CY2017Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-24462000 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22715000 USD
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
291628000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
620936000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
550312000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
980854000 USD
CY2016Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
103512000 USD
CY2017Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
79370000 USD
CY2016Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
20294000 USD
CY2017Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
36963000 USD
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
0 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
0 USD
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
28000 USD
us-gaap Other Comprehensive Income Unrealized Gain Loss On Derivatives Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodNetOfTax
28000 USD
CY2016Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
840000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3368000 USD
CY2017Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
8204000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15160000 USD
CY2016Q4 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
91434000 USD
CY2017Q2 us-gaap Other Inventory Net Of Reserves
OtherInventoryNetOfReserves
188308000 USD
CY2016Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1178000 USD
CY2017Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
397000 USD
CY2016Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
100385000 USD
CY2017Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
115920000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-7795000 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-37631000 USD
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1879000 USD
CY2017Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-19061000 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9813000 USD
CY2016Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
23100000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
40481000 USD
CY2017Q2 us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
113500000 USD
us-gaap Other Sales Revenue Net
OtherSalesRevenueNet
169940000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
242117000 USD
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
0 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
45013000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
31437000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
228942000 USD
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
477408000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
242930000 USD
us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
105310000 USD
CY2016Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2016Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2017Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
30000000 shares
CY2016Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2016Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2016Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2017Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2016Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130528000 USD
CY2017Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
193334000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
63606000 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
188693000 USD
us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
0 USD
us-gaap Proceeds From Repayments Of Long Term Debt And Capital Securities
ProceedsFromRepaymentsOfLongTermDebtAndCapitalSecurities
57000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
102177000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
272166000 USD
CY2016Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2083421000 USD
CY2017Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2261702000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
12650000 USD
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
0 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
1213000 USD
us-gaap Repayments Of Long Term Debt And Capital Securities
RepaymentsOfLongTermDebtAndCapitalSecurities
19925000 USD
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
559930000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1030042000 USD
CY2017Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
509975000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1017410000 USD
CY2016Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
1748222000 USD
CY2017Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2384897000 USD
CY2016Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
163414000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
383108000 USD
CY2017Q2 us-gaap Revenue From Related Parties
RevenueFromRelatedParties
222128000 USD
us-gaap Revenue From Related Parties
RevenueFromRelatedParties
432495000 USD
CY2016Q2 us-gaap Revenues
Revenues
1212629000 USD
us-gaap Revenues
Revenues
2413478000 USD
CY2017Q2 us-gaap Revenues
Revenues
1470116000 USD
us-gaap Revenues
Revenues
2789107000 USD
CY2016Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
834219000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1618401000 USD
CY2017Q2 us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
924133000 USD
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
1782378000 USD
CY2016Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
292038000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
581715000 USD
CY2017Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
306908000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
603754000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
273941000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
255047000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
4449245000 USD
CY2017Q2 us-gaap Stockholders Equity
StockholdersEquity
5520738000 USD
CY2016Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
235776000 USD
CY2017Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
23240000 USD
CY2016Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
3763868 shares
CY2017Q2 us-gaap Treasury Stock Shares
TreasuryStockShares
3763868 shares
CY2016Q4 us-gaap Treasury Stock Value
TreasuryStockValue
316240000 USD
CY2017Q2 us-gaap Treasury Stock Value
TreasuryStockValue
316240000 USD
CY2015Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
55249000 USD
CY2016Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
40846000 USD
CY2016Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
45851000 USD
CY2017Q2 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
55028000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
127956000 USD
us-gaap Valuation Allowances And Reserves Charged To Other Accounts
ValuationAllowancesAndReservesChargedToOtherAccounts
188858000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
142359000 USD
us-gaap Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
179681000 USD
CY2016Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
11598000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
12155000 shares
CY2017Q2 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
10103000 shares
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
9803000 shares
CY2016Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116231000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116617000 shares
CY2017Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
116137000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
115607000 shares
CY2016Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104633000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
104462000 shares
CY2017Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
106034000 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
105804000 shares
us-gaap Description Of New Accounting Pronouncements Not Yet Adopted
DescriptionOfNewAccountingPronouncementsNotYetAdopted
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recently Issued Accounting Standards </font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the FASB issued Accounting Standards Update 2014-09 ("ASU 2014-09"), </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">, which, along with subsequent amendments to ASU 2014-09 issued by the FASB, will replace existing revenue recognition guidance. The new standard requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. To achieve that core principle, an entity must identify the contract(s) with a customer, identify the performance obligations in the contract, determine the transaction price, allocate the transaction price to the performance obligations in the contract, and recognize revenue when (or as) the entity satisfies the performance obligation. The new standard will be effective for annual and interim reporting periods beginning after December 15, 2017. Early adoption is permitted, but no earlier than 2017 for calendar year-end entities. The standard allows for two transition methods - retrospectively to each prior reporting period presented or retrospectively with the cumulative effect of initially applying the standard recognized at the date of initial adoption. The Company has substantially completed its impact assessment, and does not currently expect the new standard to have a material impact on total revenues. However, substantive development milestones, which were previously recognized in the period when the milestone was achieved, will be recognized over the remaining performance period under the new standard. In connection with adopting the new standard, the Company does not anticipate implementing changes to its systems or internal controls. The Company continues to evaluate its planned method of transition and the impact of the new guidance on its financial statement disclosures.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the FASB issued Accounting Standards Update 2016-01, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Recognition and Measurement of Financial Assets and Financial Liabilities</font><font style="font-family:inherit;font-size:10pt;">. The amendments require equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. The implementation of the amendments is expected to increase the volatility of the Company's net income, as the Company holds publicly traded equity investments; however, the Company is not able to estimate the impact of adopting these amendments, as the significance of the impact will depend on the Company's equity investment balance upon adoption.</font></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued Accounting Standards Update 2016-02, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font><font style="font-family:inherit;font-size:10pt;">. The new standard requires a lessee to recognize in its balance sheet (for both finance and operating leases) a liability to make lease payments and a right-of-use asset representing its right to use the underlying asset for the lease term. The amendments are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. Early adoption is permitted. The Company is currently evaluating the impact that this guidance will have on the Company's financial statements, including related disclosures. The Company expects the new standard will have a significant impact on its controls, systems, and processes.</font></div></div>
us-gaap Revenue Recognition Revenue Reductions
RevenueRecognitionRevenueReductions
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue from product sales is recorded net of applicable provisions for rebates and chargebacks, distribution-related fees, and other sales-related deductions. </font></div></div>

Files In Submission

Name View Source Status
0001532176-17-000027-index-headers.html Edgar Link pending
0001532176-17-000027-index.html Edgar Link pending
0001532176-17-000027.txt Edgar Link pending
0001532176-17-000027-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
regn-063017x10q.htm Edgar Link pending
regn-20170630.xml Edgar Link completed
regn-20170630.xsd Edgar Link pending
regn-20170630_cal.xml Edgar Link unprocessable
regn-20170630_def.xml Edgar Link unprocessable
regn-20170630_lab.xml Edgar Link unprocessable
regn-20170630_pre.xml Edgar Link unprocessable
regn-ex_311x06302017x10q.htm Edgar Link pending
regn-ex_312x06302017x10q.htm Edgar Link pending
regn-ex_32x06302017x10q.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending